Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today ...

When it comes to recipes, I have a few nonnegotiables: simple, healthy and delicious! These creations are terrific for when you’re craving a quick breakfast or scrumptious afternoon snack: my ...

An icon of 3 horizontal dots. An icon of a paper envelope. An icon of a facebook f logo. An icon of a digital camera. An icon of a house. An icon of the Instagram logo. An icon of the LinkedIn logo.

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. President Donald Trump’s first month in office has been dizzying for U.S ...

- Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch - First of three planned Phase 3 azetukalner MDD studies ...

XENON PHARMACEUTICALS INC. Condensed Consolidated Balance Sheets (Expressed in thousands of U.S. dollars) December 31, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents and ...

BURNABY, British Columbia (AP) — BURNABY, British Columbia (AP) — Xenon Pharmaceuticals Inc. (XENE) on Thursday reported a loss of $65.7 million in its fourth quarter. On a per-share basis ...

– Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch – First of three planned Phase 3 azetukalner MDD ...